Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Complement C3 and marginal zone B cells promote IgG-mediated enhancement of RBC alloimmunization in mice
Arijita Jash, Thomas Pridmore, James B. Collins, Ariel M. Hay, Krystalyn E. Hudson, Chance John Luckey, James C. Zimring
Arijita Jash, Thomas Pridmore, James B. Collins, Ariel M. Hay, Krystalyn E. Hudson, Chance John Luckey, James C. Zimring
View: Text | PDF
Research Article Immunology

Complement C3 and marginal zone B cells promote IgG-mediated enhancement of RBC alloimmunization in mice

  • Text
  • PDF
Abstract

Administration of anti-RhD immunoglobulin (Ig) to decrease maternal alloimmunization (antibody-mediated immune suppression [AMIS]) was a landmark clinical development. However, IgG has potent immune-stimulatory effects in other settings (antibody-mediated immune enhancement [AMIE]). The dominant thinking has been that IgG causes AMIS for antigens on RBCs but AMIE for soluble antigens. However, we have recently reported that IgG against RBC antigens can cause either AMIS or AMIE as a function of an IgG subclass. Recent advances in mechanistic understanding have demonstrated that RBC alloimmunization requires the IFN-α/-β receptor (IFNAR) and is inhibited by the complement C3 protein. Here, we demonstrate the opposite for AMIE of an RBC alloantigen (IFNAR is not required and C3 enhances). RBC clearance, C3 deposition, and antigen modulation all preceded AMIE, and both CD4+ T cells and marginal zone B cells were required. We detected no significant increase in antigen-specific germinal center B cells, consistent with other studies of RBC alloimmunization that show extrafollicular-like responses. To the best of our knowledge, these findings provide the first evidence of an RBC alloimmunization pathway which is IFNAR independent and C3 dependent, thus further advancing our understanding of RBCs as an immunogen and AMIE as a phenomenon.

Authors

Arijita Jash, Thomas Pridmore, James B. Collins, Ariel M. Hay, Krystalyn E. Hudson, Chance John Luckey, James C. Zimring

×

Figure 7

MZ B cells are required for IgG2c-induced RBC alloimmunization.

Options: View larger image (or click on image) Download as PowerPoint
MZ B cells are required for IgG2c-induced RBC alloimmunization.
Using th...
Using the experimental design shown in Figure 1A, WT mice were treated with an antibody cocktail known to deplete MZ B cells (anti-CD49b plus anti-CD11c). (A) Depletion was confirmed by flow cytometry, and (B and C) treatment prevented IgG2c-induced AMIE at both the IgM and IgG levels. Robust IgG2c-induced AMIE still occurred with injection of isotype-matched controls, ruling out nonspecific effects of injection of IgG2a and IgG2b (see Supplemental Figure 3A). (D) As reported, mice with a B cell conditional deletion of Notch2 had decreased numbers of MZ B cells and (E and F) had significantly decreased IgG2c-induced AMIE at the IgM and IgG levels. The adjusted MFI was calculated by subtracting the background antibody signal on antigen-negative B6 RBCs from RBCs expressing KEL, as detailed in Methods. Each experiment was repeated a minimum of 3 times with 5–12 mice per group, and representative experiments are shown. P > 0.05 (NS), *P < 0.05, ***P < 0.001, and ****P < 0.0001, by multiple Mann-Whitney U test (B and E) and repeated-measures and 2-way ANOVA with Šidák’s multiple-comparison test (C and F).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts